Phenotype-directed clinically driven low-dose direct oral anticoagulant for atrial fibrillation.

Abstract excerpt

Clinically-driven dose reduction of direct oral anticoagulants in individuals with atrial fibrillation is prevalent worldwide. However, a paucity of evidence to tailor dose selection remained as clinical unmet need. Current doses of anticoagulant were determined largely by landmark clinical trials, in which the enrolled subjects were carefully selected and without major comorbidities. Our study reviewed the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anticoagulants
• Share to Atrial Fibrillation
• Share to Kidney